Bristol-Myers Squibb was off to what seemed like it was going to be a great day in the market today. At the opening bell, the stock was trading in the green. After the bell, we saw a continuation of upward movement, …
Bristol-Myers Squibb
Shareholders of Bristol-Myers Squibb Co. (NYSE: BMY) looking to boost their income beyond the stock’s 2.8% annualized dividend yield ... a special Seven Days for Seven Dollars invitation from Forbes.
Bristol-Myers Squibb Co. BMY, +0.66% shares sunk 7.2% in pre-market trade Friday after the company said …
Lung cancer
Bristol-Myers shares jumped 3% yesterday after a late-stage study on cancer drug Opdivo proved to be a success, leading to Deutsche Bank raising its price target on the company’s stock Bristol-Myers Squibb Co …
Cowen and Company cut shares of Bristol-Myers Squibb Company (NYSE:BMY) from an outperform rating to a market perform rating in a report released on Friday morning. They currently have $65.00 target price on the …
Bristol-Myers Squibb
Sector Gamma As increased its stake in Bristol Myers Squibb Co (BMY) by 224.37% based on its latest …
Bristol-Myers Squibb
Shares of Bristol-Myers Squibb Company (NYSE:BMY) fell 2.5% on Friday after the company announced weaker than expected quarterly earnings. The company traded as low as $46.01 and last traded at $48.01, with a …
Middle East
First, the change in the U.S. political leadership has created some uncertainty. Bristol-Myers Squibb’s stock fell nearly 5% on January 11th when the new president Donald Trump announced that he would force the industry …
Trefis1mon
Bristol-Myers Squibb
Shares of Bristol-Myers Squibb Co. (ticker: BMY) fell more than 16 percent Friday after the company announced that its Opdivo drug failed a study that would have expanded its use to lung cancer patients. BMY stock
USNews6mon
Bristol-Myers Squibb
The Donald Trump election made things worse. The threat of the now-president’s tweets about drug pricing made the sector toxic to investors. However, there was some exuberance late in 2016. We saw many experts tout …
MSN1mon
Bristol-Myers Squibb